Amgen, Inc.

The global precision genomic testing market was USD 14.65 billion in 2023, expected to reach USD 57.59 billion by 2033, driven by personalized medicine and genomic tech advancements. Key segments include oncology, next-generation sequencing, and consumables, with North America leading and Asia Pacific expected to grow fastest.

Roivant acquires mosliciguat from Bayer for pulmonary hypertension; Viridian's thyroid eye disease treatment succeeds in Phase 3; Verily alums launch Highlander Health for clinical research optimization; House passes BIOSECURE Act restricting business with Chinese biotechs; Candid Therapeutics raises $370M for bispecific antibody therapies; Merck's Keytruda faces potential competition from Akeso's ivonescimab; Penn's gene therapy ATSN-101 shows promise for rare blindness.

The Global Monoclonal Antibodies Market is projected to grow from USD 279.8 billion in 2024 to USD 804.7 billion by 2033, at a CAGR of 12.5%. North America is expected to dominate with a 47.5% share in 2024, driven by strong healthcare infrastructure and high R&D investments. Oncology is projected to lead the application segment with a 46.2% share. Major companies include Roche, Novartis, Johnson & Johnson, Pfizer, and Merck.

Geron Corporation appoints Jim Ziegler as Executive VP, Chief Commercial Officer to lead global commercial strategy and drive growth of RYTELO™, effective September 9, 2024.

Semaglutide injections reduced overall, cardiovascular, and infection-related deaths by 19%, 15%, and 23% respectively in a study of 17,000 obese and overweight patients with heart disease.

Global Monoclonal Antibodies Market to reach USD 804.7 billion by 2033, growing at a CAGR of 12.5% from USD 279.8 billion in 2024. Dominated by North America, human-derived antibodies, and oncology applications, with key players including Roche, Novartis, and Johnson & Johnson.

I-DXd (ifinatamab deruxtecan) showed clinically meaningful responses in pretreated extensive-stage SCLC patients, with a confirmed response rate of 26.1% at 8 mg/kg and 54.8% at 12 mg/kg. The 12 mg/kg dose was selected as optimal for further study.

Amgen presents new data on IMDELLTRA (tarlatamab-dlle) at 2024 WCLC, showing potential for combination with PD-L1 inhibitor as first-line maintenance therapy in ES-SCLC and sustained safety and efficacy in previously treated ES-SCLC.

Latigo Biotherapeutics appoints Tim Lugo as CFO and adds Beth Seidenberg and Jim Tananbaum to its board, aiming to advance non-opioid pain medicine development.

© 2024 Mashup Media, LLC. All rights reserved.